Compared to the parent compound 1, these inhibitors exhibit a 28-fold increase in SHMT2 inhibition, a 21-fold increase in SHMT1 inhibition, and an 11-fold increase in glycinamide ribonucleotide formyltransferase (GARFTase) inhibition [166]
doi: 10.1136/gutjnl-2018-317155 54 YuanZ.YinB.WeiD.YuanY.-R
Kawai Y, Garduo L, Theodore M, Yang J, Arinze IJ
It is also emphasized that glutamine metabolism heterogeneity and adaptability become one of the main reasons for drug resistance in tumor patients, so we explore the mechanism of cancer cells utilizing glutamine metabolism-related branched pathways as well as bypassing glutamine metabolism to participate in the occurrence of drug resistance, which provides a new diagnostic and therapeutic idea for the further clinical development of glutamine metabolism-related antitumor drugs
Olabarria, M., Noristani, H